# Convalescent Plasma in the Treatment of COVID 19

> **NCT04343261** · PHASE2 · COMPLETED · sponsor: **Trinity Health Of New England** · enrollment: 48 (actual)

## Conditions studied

- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- COVID
- Coronavirus

## Interventions

- **BIOLOGICAL:** Convalescent Plasma

## Key facts

- **NCT ID:** NCT04343261
- **Lead sponsor:** Trinity Health Of New England
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-10
- **Primary completion:** 2020-07-23
- **Final completion:** 2020-08-13
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04343261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04343261, "Convalescent Plasma in the Treatment of COVID 19". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04343261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*